{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:57:24Z","timestamp":1791244644142,"version":"4.1.0"},"reference-count":13,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reports"],"abstract":"<jats:p>We present a case of serious and progressive neuropathy shortly following the administration of the herpes zoster subunit (HZ\/su) vaccine, otherwise known as Shingrix. The progressive neuropathy occurred a week following the vaccination and progressed until discharge 16 days post-admittance. The patient\u2019s mild symptoms persist. The development of neuropathy following HZ\/su administration is exceedingly rare, with an attributable risk of three cases per million vaccines administered. A black box warning was issued for this indication, although diagnosis and treatment were not confirmed for this patient. Reporting cases like this is crucial for a comprehensive understanding of vaccine risks and to characterize the underlying etiology of these serious adverse events.<\/jats:p>","DOI":"10.3390\/reports7010005","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T07:25:07Z","timestamp":1705303507000},"page":"5","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Serious and Progressive Neuropathy Presumably Post-Shingrix Vaccination"],"prefix":"10.3390","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9232-9745","authenticated-orcid":false,"given":"Michael J.","family":"Wons","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Rocky Vista University, Ivins, UT 84738, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avani","family":"Vaghela","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Rocky Vista University, Ivins, UT 84738, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2985-1495","authenticated-orcid":false,"given":"Amna","family":"Khalid","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Rocky Vista University, Ivins, UT 84738, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-3074","authenticated-orcid":false,"given":"Benjamin D.","family":"Brooks","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Rocky Vista University, Ivins, UT 84738, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/2051013615599151","article-title":"Herpes Zoster Epidemiology, Management, and Disease and Economic Burden in Europe: A Multidisciplinary Perspective","volume":"3","author":"JohnJohnson","year":"2015","journal-title":"Ther. Adv. Vaccines"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4065\/84.9.787","article-title":"Health Care Utilization and Cost Burden of Herpes Zoster in a Community Population","volume":"84","author":"Yawn","year":"2009","journal-title":"Mayo Clin. Proc."},{"key":"ref_3","unstructured":"Maramattom, B.V., and Krishnan, P. (2023, November 10). Guillain-Barr\u00e9 Syndrome Following ChAdOx1-S\/nCoV-19 Vaccine\u2014Maramattom\u20142021\u2014Annals of Neurology\u2014Wiley Online Library. Available online: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.26143."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1177\/1060028018758431","article-title":"Shingrix: The New Adjuvanted Recombinant Herpes Zoster Vaccine","volume":"52","author":"James","year":"2018","journal-title":"Ann. Pharmacother."},{"key":"ref_5","first-page":"e4920","article-title":"Uveitis Sarcoidosis Presumably Initiated after Administration of Shingrix Vaccine","volume":"11","author":"Vante","year":"2019","journal-title":"Cureus"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1001\/jamainternmed.2021.6227","article-title":"Risk of Guillain-Barr\u00e9 Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries","volume":"181","author":"Goud","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.15585\/mmwr.mm6804a4","article-title":"Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix)\u2014United States, October 2017\u2013June 2018","volume":"68","author":"Hesse","year":"2019","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/cmi.2017.151","article-title":"Vaccine-Induced Autoimmunity: The Role of Molecular Mimicry and Immune Crossreaction","volume":"15","author":"Segal","year":"2018","journal-title":"Cell. Mol. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Nakayama, T., Sawada, A., and Ito, T. (2022). Increased Production of Inflammatory Cytokines after Inoculation with Recombinant Zoster Vaccine in Mice. Vaccines, 10.","DOI":"10.3390\/vaccines10081339"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.it.2022.02.003","article-title":"Jacobs. Guillain-Barr\u00e9 Syndrome: Expanding the Concept of Molecular Mimicry","volume":"43","author":"Laman","year":"2022","journal-title":"Trends Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1212\/WNL.0b013e3182104407","article-title":"Early recognition of poor prognosis in guillain-barre syndrome","volume":"76","author":"Walgaard","year":"2011","journal-title":"Neurology"},{"key":"ref_12","first-page":"301","article-title":"Severe Guillain-Barr\u00e9 Syndrome Following Shingrix\u00ae Vaccine Administration","volume":"10","author":"Rina","year":"2019","journal-title":"J. Neurol. Neurosci."},{"key":"ref_13","first-page":"e30717","article-title":"Recurrence of a Rare Subtype of Guillain-Barr\u00e9 Syndrome Following a Second Dose of the Shingles Vaccine","volume":"14","author":"Chohan","year":"2022","journal-title":"Cureus"}],"container-title":["Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2571-841X\/7\/1\/5\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:46:15Z","timestamp":1760103975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2571-841X\/7\/1\/5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,13]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["reports7010005"],"URL":"https:\/\/doi.org\/10.3390\/reports7010005","relation":{},"ISSN":["2571-841X"],"issn-type":[{"value":"2571-841X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,13]]}}}